<DOC>
	<DOC>NCT02518048</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-psoriatic effect of LEO 90100 aerosol foam compared with Betesil® medicated plaster</brief_summary>
	<brief_title>A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description>The products will be applied on 6 test sites (each product on 3 test sites) once daily 6 days a week (except Sundays) for 4 weeks. The application sites for each product will be determined according to random assignment. Depending on the size of the psoriasis plaques, 2 or 4 test sites will be located within the same plaque; the treatment assignment will be done pair-wise.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<criteria>Signed and dated informed consent has been obtained Subjects with a diagnosis of psoriasis vulgaris with preferably three lesions (plaques) located on arms, legs and/or trunk or at least two lesions (plaques) located on arms, legs and/or trunk. For subjects with three lesions, each lesion must have a size suitable to accommodate 2 test sites (test site area 5 cm2, distance between two test sites at least 2 cm). For subjects with two lesions, one lesion must have a size suitable to accommodate 4 test sites, and the other lesion must accommodate 2 test sites. Age 18 years or above Outpatients Female subjects must be of either nonchildbearing potential, i.e. postmenopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or, childbearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy. Female subjects who are breast feeding Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: Etanercept within 4 weeks prior to randomisation and during the trial Adalimumab, infliximab within 8 weeks prior to randomisation and during the trial Ustekinumab within 16 weeks prior to randomisation and during the trial Other products within 4 weeks/5 halflives prior to randomisation and during the trial (whichever is longer) Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4week period prior to randomisation and during the trial Subjects using phototherapy within the following time periods prior to randomisation and during the trial: PUVA: 4 weeks UVB: 2 weeks Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the trial: Potent or very potent (WHO group IIIIV) corticosteroids Subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the trial: WHO group III corticosteroids (except if used for treatment of scalp and/or facial psoriasis) Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. calcineurin inhibitors), Tar products, Salicylic acid Subjects using emollients on the selected plaques within 1 week before randomisation and during the trial Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomisation and during the trial Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>